Dexcom Expands Type 2 Diabetes Focus with New Data and Product Roadmap
Event summary
- Dexcom presented new data at ATTD 2026 showing improved A1C and weight management in non-insulin-treated Type 2 diabetes patients using Dexcom G7.
- Claims data indicated reduced DKA-related hospitalizations and ER visits for Type 1 diabetes patients using Dexcom CGM.
- Dexcom showcased its product roadmap, including upcoming features for Dexcom G7, G7 15 Day, Stelo, Clarity, and next-generation sensors.
- The company introduced a consensus-based CGM competency framework for healthcare providers through Dexcom Academy.
The big picture
Dexcom is positioning itself as a leader in glucose biosensing by expanding its focus beyond Type 1 diabetes to include Type 2 diabetes and prediabetes. The company's commitment to innovation, evidenced by its product roadmap and educational initiatives, aligns with broader industry trends toward personalized and preventive healthcare. With a strong presence at ATTD 2026, Dexcom is reinforcing its role in transforming diabetes care globally.
What we're watching
- Market Expansion
- How Dexcom's focus on Type 2 diabetes will impact its market share and revenue growth.
- Product Innovation
- The pace at which Dexcom can deliver on its product roadmap, particularly next-generation sensors.
- Regulatory Dynamics
- Whether Dexcom's CGM competency framework will gain widespread adoption among healthcare providers.
Related topics